PCN92 Cost Effectiveness of Obinutuzumab PLUS Chemotherapy Followed By Obinutuzumab Maintenance for Patient with Previously Untreated Advanced-STAGE Follicular Lymphoma in French Setting
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.229
https://www.valueinhealthjournal.com/article/S1098-3015(20)32485-2/fulltext
Title :
PCN92 Cost Effectiveness of Obinutuzumab PLUS Chemotherapy Followed By Obinutuzumab Maintenance for Patient with Previously Untreated Advanced-STAGE Follicular Lymphoma in French Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32485-2&doi=10.1016/j.jval.2020.08.229
First page :
Section Title :
Open access? :
No
Section Order :
10178